Skip to search formSkip to main contentSkip to account menu

BMS-906024

Known as: GS/pan-Notch Inhibitor BMS-906024 
An orally bioavailable, small-molecule gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, GS… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background: Lung cancer is the leading cause of cancer death worldwide. More effective treatments are needed to increase durable… 
2018
2018
2515Background: Notch signaling can be deregulated in human cancer. AL101 (formerly BMS-906024), a gamma secretase inhibitor that… 
2017
2017
Notch signaling is aberrantly activated in approximately one third of non–small cell lung cancers (NSCLC). We characterized the… 
2016
2016
Notch signaling is aberrantly activated in approximately one third of non-small cell lung cancer (NSCLC) cases, primarily through… 
Highly Cited
2015
Highly Cited
2015
Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors… 
2015
2015
Notch pathway antagonists such as γ-secretase inhibitors (GSIs) are being tested in diverse cancers, but exceptional responses… 
2015
2015
Bioanalytical analysis of toxicokinetic and pharmacokinetic samples is an integral part of small molecule drugs development and… 
2014
2014
Background: Activating mutations in Notch receptors are found in multiple hematopoietic malignancies, including > 50% of patients… 
2014
2014
Deregulation of the Notch pathway has been shown to be oncogenic in numerous tissue types including T-cell acute lymphoblastic…